{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:00:42Z","timestamp":1781870442354,"version":"3.54.5"},"reference-count":52,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Gastroenterology & Hepatology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1080\/17474124.2023.2172399","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T18:14:50Z","timestamp":1674324890000},"page":"109-117","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis"],"prefix":"10.1080","volume":"17","author":[{"given":"Cindy C.Y.","family":"Law","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia","family":"Kayal","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Mehandru","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.006"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00065-0"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.06.016"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2019.03.002"},{"key":"e_1_3_4_6_1","unstructured":"FDA approves new treatment for moderately to severely active ulcerative colitis. 2018."},{"key":"e_1_3_4_7_1","unstructured":"Fda. FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz Xeljanz XR) | FDA. 2019. p. 2017\u20132019."},{"key":"e_1_3_4_8_1","unstructured":"Fda. Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz Xeljanz XR (tofacitinib). 2021."},{"key":"e_1_3_4_9_1","unstructured":"Abbvie. RINVOQ\u00ae (upadacitinib) receives FDA Approval for the treatment of adults with moderately to severely active ulcerative colitis. 2022."},{"key":"e_1_3_4_10_1","unstructured":"AbbVie. RINVOQ [package insert]. 2022."},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2020.100075"},{"issue":"1","key":"e_1_3_4_12_1","first-page":"139","article-title":"Antibodies against small molecules","volume":"27","author":"Clementi ME","year":"1991","unstructured":"Clementi ME, Marini S, Cond\u00f2 SG, et al. Antibodies against small molecules. Ann Ist Super Sanita. 1991;27(1):139\u2013143.","journal-title":"Ann Ist Super Sanita"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.11.4.2057-2065.1991"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00287"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i28.4055"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.34.20494"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8197455"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2571188"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2004-5-12-253"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"issue":"2","key":"e_1_3_4_21_1","first-page":"II45","article-title":"JAK1 inhibition and inflammatory bowel disease","volume":"60","author":"Harris C","year":"2021","unstructured":"Harris C, Cummings JRF. JAK1 inhibition and inflammatory bowel disease. Rheumatol (United Kingdom). 2021;60(Supplement_2):II45\u2013II51.","journal-title":"Rheumatol (United Kingdom)"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.17.2.695"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(92)90105-L"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.13.040195.002101"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1995.tb07128.x"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0419-y"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.02.030"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00581-5"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab232.077"},{"key":"e_1_3_4_30_1","volume-title":"Rapidity of symptom control with upadacitinib induction therapy in patients with moderately to severely active ulcerative colitis: results from two randomized phase 3 studies","author":"Loftus E","year":"2021","unstructured":"Loftus E, Takeuchi K, Gao X, et al., editor. Rapidity of symptom control with upadacitinib induction therapy in patients with moderately to severely active ulcerative colitis: results from two randomized phase 3 studies. Las Vegas Nevada: ACG 2021; 2021."},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000776956.67877.43"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab232.080"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab232.078"},{"key":"e_1_3_4_34_1","volume-title":"OP33 Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC)","author":"Colombel JF","year":"2022","unstructured":"Colombel JF, Cao Q, Ghosh S, et al. editors. OP33 Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC). Results from the UPA Phase 3 programme 2022; San DiegoSupplement_1)."},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326390"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00377-0"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab232.033"},{"key":"e_1_3_4_38_1","unstructured":"Food Drug A. FDA requires warnings about increased risk of serious heart-related events cancer blood clots and death for JAK inhibitors that treat certain chronic inflammatory conditions. 2021."},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222405"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002012"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16712"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab011"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.001"},{"key":"e_1_3_4_45_1","unstructured":"Prevention CfDCa. Clinical considerations for use of recombinant zoster vaccine (RXV Shingrix) in immunocompromised adults aged >19 years. 2022."},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz025"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11236894"},{"key":"e_1_3_4_48_1","doi-asserted-by":"crossref","unstructured":"Grundy SM Stone NJ Bailey AL et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082\u2013e1143.","DOI":"10.1161\/CIR.0000000000000698"},{"key":"e_1_3_4_49_1","unstructured":"European Commission approves RINVOQ (upadacitinib) for the treatment of aduts with moderate to severe ulcerative colitis. 2022."},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab099"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab232.497"},{"issue":"16","key":"e_1_3_4_52_1","doi-asserted-by":"crossref","first-page":"i008","DOI":"10.1093\/ecco-jcc\/jjab232.007","article-title":"OP08 The effects of maintenance therapy with upadacitinib on abdominal pain, bowel urgency, and fatigue in patients with moderately to severely active Ulcerative Colitis: phase 3 U-ACHIEVE maintenance results","volume":"01","author":"Danese S","year":"2022","unstructured":"Danese S, Tran J, D\u2019Haens G, et al. OP08 The effects of maintenance therapy with upadacitinib on abdominal pain, bowel urgency, and fatigue in patients with moderately to severely active Ulcerative Colitis: phase 3 U-ACHIEVE maintenance results. J Crohn\u2019s Colitis. 2022;01\/21(16):i008\u2013i010.","journal-title":"J Crohn\u2019s Colitis"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00778-4"}],"container-title":["Expert Review of Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474124.2023.2172399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:34:45Z","timestamp":1770896085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474124.2023.2172399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1080\/17474124.2023.2172399"],"URL":"https:\/\/doi.org\/10.1080\/17474124.2023.2172399","relation":{},"ISSN":["1747-4124","1747-4132"],"issn-type":[{"value":"1747-4124","type":"print"},{"value":"1747-4132","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierh20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierh20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-10-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}